Trileptal 300 mg film-coated tablets
Authorisation PPA1463/154/002 · IMED Healthcare Ltd.,
- Licence holder
- IMED Healthcare Ltd., (all products →)
- Active substance
- Oxcarbazepine
- Dosage form
- Film-coated tablet
- Route of administration
- Oral use
- ATC codes
- N03AF, N03AF02
- First authorised
- 15/01/2021
- Prescription status
- Product subject to prescription which may be renewed (B)
- Supply
- Supply through pharmacies only
- Legal basis
- Parallel importation notified in accordance with Article 76(3) of Directive 2001/83/EC
Oxcarbazepine: supply and approvals
11 authorised products on the HPRA list contain Oxcarbazepine. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 19 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 19 Nov 2026)
- Germany (BfArM)
- 1 supply notice, e.g. Oxcarbazepin - 1 A Pharma 60 mg/ml Suspension zum Einnehmen (9 May 2025 to 30 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
Parallel import (PPA). A parallel product authorisation: the HPRA allows this product to be imported from another EU or EEA country and sold in Ireland. It has been authorised for 5 years (since 15 January 2021). The HPRA list does not say whether it is on sale.
Other medicines with Oxcarbazepine in Ireland
10 other products on the HPRA list contain Oxcarbazepine, from 4 licence holders; 4 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Trileptal 150 mg Film-coated tablets | Novartis Ireland Limited | National authorisation (PA) | Marketed |
| Trileptal 300 mg Film-coated tablets | Novartis Ireland Limited | National authorisation (PA) | Marketed |
| Trileptal 60 mg/ml Oral Suspension | Novartis Ireland Limited | National authorisation (PA) | Marketed |
| Trileptal 600 mg Film-coated tablets | Novartis Ireland Limited | National authorisation (PA) | Marketed |
| Trileptal 300 mg film-coated tablets | PCO Manufacturing Ltd. | Parallel import (PPA) | Not stated |
| Trileptal 60 mg/ml Oral Suspension | Originalis B.V. | Parallel import (PPA) | Not stated |
| Trileptal 60 mg/ml Oral Suspension | IMED Healthcare Ltd., | Parallel import (PPA) | Not stated |
| Trileptal 60 mg/ml oral suspension | PCO Manufacturing Ltd. | Parallel import (PPA) | Not stated |
| Trileptal 600 mg film-coated tablets | PCO Manufacturing Ltd. | Parallel import (PPA) | Not stated |
| Trileptal 600 mg film-coated tablets | IMED Healthcare Ltd., | Parallel import (PPA) | Not stated |
Other substances in ATC group N03AF
The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 3 other active substances share the group N03AF with this product:
Carbamazepine (7) · Eslicarbazepine acetate (5) · Rufinamide (2)
Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.
The licence holder
IMED Healthcare Ltd., holds 178 products on the HPRA list, with 119 different active substances; 1 of the products is marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 20 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.